ERBB2 and glioblastoma: A strategy of using combination targeting of HER2 and IL13Rα2 by bispecific T cells in glioblastoma was shown to be more efficient in eliminating tumor cells and showed less antigen escape variants compared with the CAR-T cells targeting HER2 alone in both in vitro and in vivo mouse xenograft models 82.